Novartis gets another approval for everolimus in EU PharmaTimes Specifically, the approval for Volubia (everolimus) is for aforementioned patients who are at risk of complications (based on factors such as tumour size or presence of aneurysm) but who do not require immediate surgery. Novartis noted that this marks ... |
